Authorized purpose: The Automated Bone Mineral Density Software Module measures bone mineral density from existing CT by averaging Hounsfield units in trabecular vertebral bone and can calculate age- and sex-referenced Z and T scores.
Clinical role
Post-processing and opportunistic BMD measurement from existing CT.
Images and patients
CT/CTA · Trabecular vertebral bone and lumbar spine
Key limitation
Keep in mind: The FDA labeling states that the module is not a replacement for DXA or another dedicated BMD examination. Results are opportunistic CT measurements and require review of scan quality, calibration, anatomy, and clinical context.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The Automated Bone Mineral Density Software Module measures bone mineral density from existing CT by averaging Hounsfield units in trabecular vertebral bone and can calculate age- and sex-referenced Z and T scores.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Trabecular vertebral bone and lumbar spine Input: Existing CT DICOM studies with acquisition metadata and patient age and sex.
Who uses it?Intended users: Radiologists and healthcare providers who review CT-derived bone-mineral-density information.
What does the software produce?Output: Vertebral segmentation, trabecular Hounsfield-unit measurements, calculated BMD, Z and T scores, snapshots, and measurements for human review.
What is its most important limitation?Key limitation: The FDA labeling states that the module is not a replacement for DXA or another dedicated BMD examination. Results are opportunistic CT measurements and require review of scan quality, calibration, anatomy, and clinical context.
Clinical takeaway. Clinical role: The Automated Bone Mineral Density Software Module measures bone mineral density from existing CT by averaging Hounsfield units in trabecular vertebral bone and can calculate age- and sex-referenced Z and T scores.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation testing and two performance studies: Study 1 used 993 quantitative CT (QCT) readings of asymptomatic cases, and Study 2 used 172 asymptomatic cases who underwent whole-body DXA and CT scans. ABMD Software correlated with manual QCT-based BMD measurement (r = 0.97, p<0.01) and with DXA BMD measurement (r = 0.72, p<0.01). Clinical testing was not required. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The Automated Bone Mineral Density Software Module measures bone mineral density from existing CT by averaging Hounsfield units in trabecular vertebral bone and can calculate age- and sex-referenced Z and T scores.
The FDA labeling states that the module is not a replacement for DXA or another dedicated BMD examination. Results are opportunistic CT measurements and require review of scan quality, calibration, anatomy, and clinical context.
The exact FDA document reports software verification and validation testing and two performance studies: Study 1 used 993 quantitative CT (QCT) readings of asymptomatic cases, and Study 2 used 172 asymptomatic cases who underwent whole-body DXA and CT scans. ABMD Software correlated with manual QCT-based BMD measurement (r = 0.97, p<0.01) and with DXA BMD measurement (r = 0.72, p<0.01). Clinical testing was not required. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software Verification and Validation testing was completed to demonstrate the safety and effectiveness of the device." … "Study 1 Study 2 Reference 993 quantitative CT (QCT) readings of a 172 asymptomatic cases who underwent Dataset cohort of asymptomatic cases who whole-body DXA scans as well as CT underwent CT scans. scans.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation testing and two performance studies: Study 1 used 993 quantitative CT (QCT) readings of asymptomatic cases, and Study 2 used 172 asymptomatic cases who underwent whole-body DXA and CT scans. ABMD Software correlated with manual QCT-based BMD measurement (r = 0.97, p<0.01) and with DXA BMD measurement (r = 0.72, p<0.01). Clinical testing was not required. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software Verification and Validation testing was completed to demonstrate the safety and effectiveness of the device." … "Study 1 Study 2 Reference 993 quantitative CT (QCT) readings of a 172 asymptomatic cases who underwent Dataset cohort of asymptomatic cases who whole-body DXA scans as well as CT underwent CT scans. scans.". Read from the exact FDA decision document on 2026-11-14.
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K213760 FDA evidence package for ABMD Software
DesignFDA 510(k) decision evidence and product verification for the exact submission.
PopulationTrabecular vertebral bone and lumbar spine
Scopeexact submission
Tested versionAutomated Bone Mineral Density Software Module
IndependenceSponsor or vendor study
K213760
FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
No record matched K213760 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Existing CT DICOM studies with acquisition metadata and patient age and sex.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes existing CT DICOM input, metadata extraction, vertebral segmentation, and exported snapshots and measurements.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Vertebral segmentation, trabecular Hounsfield-unit measurements, calculated BMD, Z and T scores, snapshots, and measurements for human review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Vertebral segmentation, trabecular Hounsfield-unit measurements, calculated BMD, Z and T scores, snapshots, and measurements for human review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Use by radiologists and healthcare providers who review ct-derived bone-mineral-density information. Follow the exact labeling, local training, supervision, and escalation requirements.
Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads
No evidence was promoted. The records concern generic bone-mineral-density topics or the unrelated Abiomed brand and do not identify the HeartLung ABMD software, tested version, or K213760. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price or commercial contract for the exact submission and version was identified.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.
Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.